Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome

Background. Polycystic ovary syndrome (PCOS) is a major endocrine abnormality that affects women of reproductive age. Oral contraceptive pills are usually the first choice of treatment for PCOS when fertility is not desired. Metformin, an insulin-sensitizing drug, has been shown to improve such metabolic abnormality. Aim. To compare the effects of a contraceptive pill in combination with metformin on the clinical, endocrine and metabolic parameters in obese and non-obese patients with PCOS. Methods. Sixty PCOS patients (25 obese, 35 non-obese) were enrolled in this prospective clinical study. PCOS was defined according to the Rotterdam criteria. Patients were randomized to oral treatment with Diane35® (35 μg ethinyl estradiol plus 2 mg cyproterone acetate), metformin or a combination of Diane35/metformin for 3 months. Body mass index (BMI), waist-to-hip ratio (WHR), Ferriman–Gallwey (FG) score, leuteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, fasting insulin and glucose/insulin ratio were measured at baseline and at the end of treatment. Results. Diane35 resulted in a higher reduction of FG score in both obese and non-obese PCOS patients compared with metformin. Menstrual regularity was restored in all PCOS patients treated with Diane35 compared with only 28% of those receiving metformin. Metformin significantly decreased BMI and WHR in obese patients (p < 0.05). Testosterone levels decreased in all three groups. LH levels and LH/FSH ratio decreased with Diane35 and Diane35/metformin in both obese and non-obese patients. Metformin significantly decreased fasting insulin concentrations (p < 0.05 and p < 0.01) and increased the insulin sensitivity (p < 0.05) in both obese and non-obese PCOS patients, while no significant changes were observed in the Diane35 group. In addition, insulin levels also decreased (p < 0.05) in the Diane35/metformin group. Conclusions. Our data show that a combination of metformin and contraceptive pill may be more effective in suppressing the hyperandrogenemia of obese and non-obese PCOS patients than metformin alone and may reduce insulin levels more than contraceptive pill alone. Hence, combined treatment may become a more effective therapeutic option for PCOS.

[1]  H. Escobar-Morreale,et al.  Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[2]  N. Johnson,et al.  Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. , 2007, Human reproduction.

[3]  L. Moran,et al.  Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. , 2007, The Cochrane database of systematic reviews.

[4]  E. Baraldi,et al.  Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[5]  R. Norman,et al.  Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. , 2006, The Journal of clinical endocrinology and metabolism.

[6]  B. Okopień,et al.  Update on the management of polycystic ovary syndrome. , 2006, Pharmacological reports : PR.

[7]  S. Misevska,et al.  Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. , 2006, Prilozi.

[8]  A. Biri,et al.  The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome , 2005, Journal of endocrinological investigation.

[9]  S. Mittal,et al.  Metformin therapy in women with polycystic ovary syndrome , 2004, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[10]  M. Dei,et al.  The Management of Polycystic Ovary Syndrome , 2003, Annals of the New York Academy of Sciences.

[11]  F. Petraglia,et al.  Insulin-lowering agents in the management of polycystic ovary syndrome. , 2003, Endocrine reviews.

[12]  I. Vauhkonen,et al.  Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. , 2003, The Journal of clinical endocrinology and metabolism.

[13]  D. Jakubowicz,et al.  A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. , 2003, The Journal of clinical endocrinology and metabolism.

[14]  T. Kazerooni,et al.  Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome , 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[15]  P. Moghetti.  Insulin resistance: what is its role in the polycystic ovary syndrome? , 2002 .

[16]  F. Durmuşoǧlu,et al.  Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. , 2002, Human reproduction.

[17]  J. Jensen,et al.  Health benefits of oral contraceptives. , 2000, Obstetrics and gynecology clinics of North America.

[18]  A. Taylor,et al.  Insulin-lowering medications in polycystic ovary syndrome. , 2000, Obstetrics and gynecology clinics of North America.

[19]  A. Duleba,et al.  Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. , 2000, Fertility and sterility.

[20]  A. O. Gurol,et al.  Influence of insulin resistance on total renin level in normotensive women with polycystic ovary syndrome. , 2000, Fertility and sterility.

[21]  A. Bagnoli,et al.  A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. , 1999, The Journal of clinical endocrinology and metabolism.

[22]  T. Key,et al.  Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. , 1998, The Journal of clinical endocrinology and metabolism.

[23]  D. Finegood,et al.  A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. , 1998, The Journal of clinical endocrinology and metabolism.

[24]  A. Dunaif,et al.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. , 1997, Endocrine reviews.

[25]  C. Glueck,et al.  Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. , 1994, Metabolism: clinical and experimental.

[26]  M. Kim,et al.  Hirsutism: implications, etiology, and management. , 1981, American journal of obstetrics and gynecology.

[27]  M. Muñoz-Torres,et al.  Encuesta sobre prctica clnica en el hiperparatiroidismo primario , 2006 .

[28]  J. Nestler,et al.  Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? , 2004, Reproductive biomedicine online.

[29]  C. Battaglia,et al.  Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. , 2004, Fertility and sterility.

[30]  P. Moghetti.  Insulin resistance: what is its role in PCOS? , 2002 .

[31]  D. Cibula,et al.  Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. , 2002, Human reproduction.

[32]  R. Rosenfield.  Current concepts of polycystic ovary syndrome. , 1997, Bailliere's clinical obstetrics and gynaecology.